Akebia Therapeutics, Inc. (AKBA)
0.8786
-0.06
(-6.51%)
USD |
NASDAQ |
Aug 28, 16:00
0.8784
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Cash from Operations (Quarterly) : 3.525M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.525M |
| March 31, 2026 | -21.21M |
| December 31, 2025 | 31.13M |
| September 30, 2025 | 28.10M |
| June 30, 2025 | 22.34M |
| March 31, 2025 | -13.59M |
| December 31, 2024 | -4.466M |
| September 30, 2024 | -6.695M |
| June 30, 2024 | -10.07M |
| March 31, 2024 | -19.43M |
| December 31, 2023 | -2.308M |
| September 30, 2023 | -7.167M |
| June 30, 2023 | 3.629M |
| March 31, 2023 | -17.54M |
| December 31, 2022 | -54.68M |
| September 30, 2022 | 33.80M |
| June 30, 2022 | -30.66M |
| March 31, 2022 | -21.62M |
| December 31, 2021 | -62.81M |
| September 30, 2021 | -56.27M |
| June 30, 2021 | -63.14M |
| March 31, 2021 | -70.75M |
| December 31, 2020 | -30.78M |
| September 30, 2020 | -27.24M |
| June 30, 2020 | 37.22M |
| Date | Value |
|---|---|
| March 31, 2020 | -89.59M |
| December 31, 2019 | -92.14M |
| September 30, 2019 | 10.99M |
| June 30, 2019 | -38.37M |
| March 31, 2019 | -137.93M |
| December 31, 2018 | -73.70M |
| September 30, 2018 | -12.46M |
| June 30, 2018 | 8.996M |
| March 31, 2018 | -20.33M |
| December 31, 2017 | -16.38M |
| September 30, 2017 | -54.62M |
| June 30, 2017 | 24.36M |
| March 31, 2017 | -9.528M |
| December 31, 2016 | 95.67M |
| September 30, 2016 | -28.24M |
| June 30, 2016 | -26.96M |
| March 31, 2016 | 17.43M |
| December 31, 2015 | -22.91M |
| September 30, 2015 | -9.031M |
| June 30, 2015 | -12.12M |
| March 31, 2015 | -8.347M |
| December 31, 2014 | -9.203M |
| September 30, 2014 | -5.603M |
| June 30, 2014 | -6.669M |
| March 31, 2014 | -6.008M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Emergent BioSolutions, Inc. | 56.10M |
| Exelixis, Inc. | 307.74M |
| ADMA Biologics, Inc. | 29.54M |
| Arcutis Biotherapeutics, Inc. | 12.64M |
| Relay Therapeutics, Inc. | -54.11M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -4.079M |
| Cash from Financing (Quarterly) | -6.538M |
| Free Cash Flow | 40.26M |
| Free Cash Flow Per Share (Quarterly) | 0.0091 |
| Free Cash Flow to Equity (Quarterly) | 9.555M |
| Free Cash Flow to Firm (Quarterly) | 5.541M |
| Free Cash Flow Yield | 17.03% |